Azenta Reports Q3 Fiscal 2026 Revenue of $161M, Up 12% YoY

Azenta, Inc.

Revenue from continuing operations was $161M, up 12% year over year; organic growth was 9%.
Sample Management Solutions revenue rose 14% to $88M; Multiomics revenue rose 10% to $73M.
Diluted EPS from continuing operations was ($0.03); total diluted EPS was $0.05, compared to ($1.05) a year ago.
Adjusted EBITDA from continuing operations was $18.5M, with margin of 11.4%.
Sale of B Medical Systems closed on July 1, 2026; results reported as discontinued operations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.